HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pitt, T L Articles by Stefanidou, M Search for Related Content PubMed PubMed Citation Articles by Pitt, T L Articles by Stefanidou, M

Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents

Laboratory of HealthCare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, London NW9 5HT, UK

Correspondence to:
Correspondence to:
Dr T L Pitt, Laboratory of HealthCare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK;
Tyrone.Pitt{at}HPA.org.uk

ABSTRACT
Background: Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown.

Methods: The susceptibility of 417 CF patient isolates of P aeruginosa from 17 hospitals to six commonly prescribed antibiotics were examined. Isolates were tested by an agar break point dilution method and E-tests according to British Society of Antimicrobial Chemotherapy guidelines. Genotyping of isolates was performed by XbaI DNA macrorestriction and pulsed field gel electrophoresis.

Results: 38% of isolates were susceptible to all of the agents tested; almost half were resistant to gentamicin compared with ceftazidime (39%), piperacillin (32%), ciprofloxacin (30%), tobramycin (10%), and colistin (3%). Approximately 40% were resistant to two or more compounds with ceftazidime in combination with gentamicin, piperacillin or ciprofloxacin being the most common cross resistances. Resistance rates were generally similar to those reported recently from the USA and Germany. A selection of resistant isolates proved to be predominantly genotypically distinct by XbaI DNA macrorestriction but six pairs from three centres had similar genotypes.

Conclusions: The level of resistance to front line antipseudomonal agents, with the exception of colistin, is disturbingly high. The prudent use of antimicrobial drugs and closer monitoring of accumulation of resistant strain populations should be actively considered.

Keywords: cystic fibrosis; Pseudomonas aeruginosa; antimicrobial resistance

This article has been cited by other articles:

				A Smyth, S Lewis, C Bertenshaw, I Choonara, J McGaw, and A Watson Case-control study of acute renal failure in patients with cystic fibrosis in the UK Thorax, June 1, 2008; 63(6): 532 - 535. [Abstract] [Full Text] [PDF]

				A Smyth and J S Elborn Exacerbations in cystic fibrosis: 3 {middle dot} Management Thorax, February 1, 2008; 63(2): 180 - 184. [Abstract] [Full Text] [PDF]

				B. Deslouches, I. A. Gonzalez, D. DeAlmeida, K. Islam, C. Steele, R. C. Montelaro, and T. A. Mietzner De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia J. Antimicrob. Chemother., September 1, 2007; 60(3): 669 - 672. [Abstract] [Full Text] [PDF]

				J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507. [Abstract] [Full Text] [PDF]

				C. Bertenshaw, A. R Watson, S. Lewis, and A. Smyth Survey of acute renal failure in patients with cystic fibrosis in the UK Thorax, June 1, 2007; 62(6): 541 - 545. [Abstract] [Full Text] [PDF]

				F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311. [Abstract] [Full Text] [PDF]

				B. Deslouches, K. Islam, J. K. Craigo, S. M. Paranjape, R. C. Montelaro, and T. A. Mietzner Activity of the De Novo Engineered Antimicrobial Peptide WLBU2 against Pseudomonas aeruginosa in Human Serum and Whole Blood: Implications for Systemic Applications Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3208 - 3216. [Abstract] [Full Text] [PDF]

				K. Poole Aminoglycoside Resistance in Pseudomonas aeruginosa Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487. [Full Text] [PDF]

				E. Kugelberg, S. Lofmark, B. Wretlind, and D. I. Andersson Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa J. Antimicrob. Chemother., January 1, 2005; 55(1): 22 - 30. [Abstract] [Full Text] [PDF]

				M. Hogardt, S. Schmoldt, M. Gotzfried, K. Adler, and J. Heesemann Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients J. Antimicrob. Chemother., December 1, 2004; 54(6): 1057 - 1061. [Abstract] [Full Text] [PDF]

				M.R. O'Carroll, M.W. Syrmis, C.E. Wainwright, R.M. Greer, P. Mitchell, C. Coulter, T.P. Sloots, M.D. Nissen, and S.C. Bell Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units Eur. Respir. J., July 1, 2004; 24(1): 101 - 106. [Abstract] [Full Text] [PDF]